Nexplanon implant

Quick links

Choose a section

Quick links to important sections

Advertisements

Nexplanon implant

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Nexplanon implant

Property Description
Active ingredient Etonogestrel (INN)
Form Single-rod subdermal implant
Pharmacological class Progestogen-only contraceptive
Common use Prevention of pregnancy
Origin Synthetic derivative

Defining the Nexplanon Implant: A Progestogen-Only LARC

The Nexplanon implant is a highly effective, long-acting, reversible hormonal contraceptive used for the prevention of pregnancy. This medicine is pharmacologically classified as a progestogen-only contraceptive, containing the single synthetic hormone, etonogestrel, and is designed to provide continuous systemic delivery. The system is clinically recognized as a Long-Acting Reversible Contraceptive (LARC), distinguishing it from methods requiring daily or monthly attention, and offering sustained delivery over its duration of action. The inherent simplicity of the LARC method makes it a preferred option for individuals seeking consistent efficacy.

Composition and Form: The Etonogestrel Subdermal Delivery System

The single active ingredient is etonogestrel (INN), which is a potent synthetic derivative of the progestin desogestrel. The unique dosage form is a flexible, non-biodegradable single-rod subdermal implant designed specifically for insertion beneath the skin of the upper arm. This particular delivery mechanism is supported by pharmacological studies demonstrating the steady and prolonged release of etonogestrel into the systemic circulation.

A distinctive feature of this implant is the inclusion of barium sulfate. This additive renders the device radiopaque, a property that is highly advantageous to healthcare providers as it allows the implant's position to be confirmed via standard imaging tools, ensuring proper placement and facilitating localization for eventual removal.

High-Level Action: The Principle of Contraceptive Efficacy

The core purpose of the Nexplanon implant is achieved through a sustained, low-dose hormonal effect that establishes an environment consistently unsuitable for conception. This efficacy results from the continuous delivery of etonogestrel, which initiates synchronized biological effects, primarily working by suppressing ovulation and causing the cervical mucus to thicken. These synchronized actions provide robust, continuous protection, making the implant a dependable long-term solution for individuals seeking consistent contraception.

Regulatory References

  1. NIH Bookshelf: Clinical Review Report on Etonogestrel Extended-Release Subdermal Implant (Nexplanon)
Advertisements

What side effects are possible with Nexplanon implant?

Possible Side Effects and Safety Information

The regulatory documentation for the Nexplanon implant, which contains etonogestrel, details possible adverse reactions classified by both frequency and the System Organ Class (SOC) affected. The most frequently reported adverse drug reactions involve disturbances in normal bleeding patterns. Some changes in bleeding patterns are reported to be more frequent during the initial months following insertion.

Frequency-Classified Adverse Reactions

Classification Examples of Reactions (SOC)
Very Common (≥ 1/10) Disturbances in bleeding pattern, headache, implant site reaction, acne, emotional lability, breast tenderness/pain, vaginal infection.
Common (≥ 1/100 to < 1/10) Dizziness, nausea, abdominal pain, alopecia, back pain, increased appetite, weight gain, dysmenorrhea, pelvic pain, ovarian cyst, fatigue, hot flushes, pain.

Serious Adverse Reactions and Restrictions

Official labeling mandates the inclusion of warnings concerning serious adverse reactions associated with hormonal contraceptives. These include the potential for thromboembolic events (such as deep vein thrombosis and pulmonary embolism) and the risk of hepatic tumors (benign or malignant). If conception occurs during use, there is also a recognized risk of ectopic pregnancy.

Use of the implant is contraindicated in individuals with active venous thromboembolic disease, known or suspected progestogen-sensitive malignancies (like breast cancer), or the presence of benign or malignant liver tumors. Administration-site complications, such as implant migration or abscess formation, are also documented safety considerations.

Advertisements

Overdose and Emergency Response

Regulatory labeling notes that a typical etonogestrel hormonal overdose is considered unlikely due to the fixed, controlled release nature of the subdermal implant. The official regulatory focus is instead on severe, emergent complications that require urgent clinical management.

Documented Overdose Presentations

Documented manifestations requiring immediate action include signs of thrombosis, such as sudden partial vision loss, severe chest pain, or unexplained slurred speech. Other documented clinical signs are related to device complications, specifically when the implant cannot be palpated at the insertion site, which may indicate deep insertion or migration.

When Immediate Medical Help is Required

Regulators mandate that patients seek immediate medical attention for any signs of a vascular event. The most serious outcomes described involve implant migration to the vasculature, including the pulmonary artery or the lung, which is classified as a life-threatening risk. Immediate removal of the implant is required by regulatory instruction upon diagnosis of a thrombotic event, uncontrolled hypertension, or jaundice.

If the implant cannot be felt at any time, patients must contact their healthcare provider as soon as possible. Imaging techniques and potentially surgical or endovascular procedures may be required for localization and removal in cases of migration. Treatment for any acute hormonal effects is generally restricted to symptomatic and supportive management, as no specific antidote is known.

Advertisements

Therapeutic Uses of Nexplanon implant

Quick Facts

  • Approved Use: A method to prevent pregnancy in women.
  • Therapeutic Domain: Contraception/Family Planning.
  • Duration: Provides continuous contraceptive support for a period of up to three years.

What Nexplanon Implant Addresses: Main Uses and Benefits

Nexplanon is a prescribed subdermal insert used to support the prevention of pregnancy in women. It is a long-acting, reversible method of hormonal contraception, providing a path to manage family planning for up to three years.

The use of Nexplanon assists in reducing the likelihood of conception by working to influence hormonal processes related to reproduction. This includes action that may inhibit the release of an egg from the ovary and promote changes in cervical mucus, which can contribute to the contraceptive effect. Its mechanism of action supports a reliable, continuous presence of a progestin hormone without the requirement for a user to recall daily administration.

Due to its placement and long duration of action, this method offers convenience in managing contraceptive needs over several years. Once inserted by a healthcare professional, the implant maintains its function until it reaches the end of its three-year period, or until it is removed by a clinician if the user seeks a return to fertility or wishes to discontinue use.

Advertisements

Eligibility and Restrictions for Use

The Nexplanon implant is approved for use by women of reproductive age to prevent pregnancy. Eligibility is strictly defined by regulatory criteria, distinguishing between absolute prohibitions and conditional use.

Contraindications

Use is contraindicated and the implant must not be used by women with:

  • Known or suspected pregnancy.
  • Current or past history of thrombosis or thromboembolic disorders (e.g., blood clots).
  • Liver tumors (benign or malignant) or active liver disease.
  • Known or suspected breast cancer or other progestin-sensitive cancers.
  • Undiagnosed abnormal genital bleeding.

Population-Specific Limitations

Age-Related Eligibility: The implant is not indicated for use in individuals who have not yet reached menarche (first menstrual period) or in postmenopausal women.

Physiological Status: While generally allowed during lactation, insertion is not recommended until after the fourth postpartum week.

Conditional Use: The regulatory label specifies that the implant must be removed if blood pressure rises significantly and becomes uncontrolled, or if jaundice occurs. Efficacy may be reduced over time in overweight women. Use in patients with diabetes or renal impairment requires caution and monitoring.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of the etonogestrel implant is predominantly defined by pharmacokinetic interactions that alter the plasma concentration of the active ingredient. Co-administration with certain drugs and herbal products that are inducers of the CYP3A4 enzyme system results in a documented decrease in etonogestrel exposure, which may diminish the contraceptive efficacy.

Exposure-Reducing Substances (Enzyme Inducers):

Category Examples (listed in labeling)
Anticonvulsants Carbamazepine, Phenytoin, Topiramate, Felbamate
Anti-infectives Rifampin, Griseofulvin
Herbal Products St. John's wort (Hypericum perforatum)

Co-administration with HIV and Hepatitis C virus (HCV) medicines is also associated with unpredictable changes (both increase and decrease) in etonogestrel concentrations. The regulatory label includes a formal use restriction against co-administration with Ombitasvir, Paritaprevir, and Ritonavir pm Dasabuvir.

Etonogestrel may also exert a pharmacodynamic effect on other drugs, leading to altered plasma levels. Specifically, the implant may increase the plasma concentration of cyclosporine and decrease the concentration of lamotrigine. Due to the prolonged effect of enzyme inducers, additional non-hormonal contraception must be continued for 28 days after stopping the interacting medicine or herbal product.

Advertisements

Mechanism of Action

The Nexplanon implant delivers etonogestrel, a progestin. Its mechanism of action involves three primary biological effects on the female reproductive system: ovulation inhibition, cervical mucus alteration, and endometrial modification. These effects are distinct and contribute cumulatively to the overall mechanistic profile.

Pharmacologic Suppression of Ovulation

Etonogestrel acts primarily by mimicking the action of natural progesterone, providing continuous negative feedback predominantly on the hypothalamus and pituitary gland. This feedback suppresses the surge of Luteinizing Hormone (LH)—a stimulus for ovarian follicle rupture—and partially suppresses Follicle-Stimulating Hormone (FSH), inhibiting follicular maturation. The physiological consequence of this is anovulation, preventing the cyclical release of an ovum.

Alteration of Cervical Mucus Consistency

Etonogestrel acts directly on the cervical glands, inducing a physicochemical change in the cervical mucus. This process decreases water content and increases viscosity, resulting in the formation of a thick, tenacious mucous plug. This physical impedance limits the number of motile sperm able to enter the upper reproductive tract, operating as a secondary mechanism influencing sperm transit.

Modulation of the Endometrial Lining

Etonogestrel acts as an agonist for the progesterone receptors in the endometrial lining. Continuous, non-cyclical exposure causes the endometrium to become thin, quiescent, and decidualized. This structural modification results in an atrophic and non-secretory state, rendering the tissue non-receptive to implantation, which provides a tertiary mechanistic effect.

Advertisements

Dosage and Administration Information

How to Use Nexplanon Implant

The administration of the Nexplanon implant is defined by a standardized procedural protocol, strictly supervised by trained healthcare professionals. The system is designed to provide continuous, long-term hormonal delivery and does not involve any daily user-administered dosing.


Administration Scope

The implant, which contains 68 mg of etonogestrel, is administered via the subdermal route (beneath the skin). Only one device is inserted per course of treatment, with an initial release rate of approximately 60 – 70 mcg of etonogestrel per day, which gradually decreases over time. The administration site is the inner side of the non-dominant upper arm.


Procedural and Duration Requirements

Insertion and removal must be performed only by healthcare professionals (HCPs) who are specifically trained in the procedural technique. After the single insertion procedure, the implant provides continuous hormonal support for a duration of up to three years. It is mandatory that the device be removed no later than the end of this three-year period. A new implant may be inserted immediately after removal if continued support is desired.

Specific timing instructions govern when the implant is inserted; this is based on the woman's prior contraceptive method or menstrual cycle. Furthermore, the implant's presence must be immediately confirmed by palpation (feeling the device) following the procedure to ensure correct placement.


Population-Specific Considerations

While safety and efficacy have been established for women between the ages of 18 and 40, official labeling notes that the healthcare provider may consider the earlier replacement of the implant for heavier women.

Advertisements

Recent Clinical Evidence

Research Evidence Overview for Nexplanon Implant

Evidence for Use in Pregnancy Prevention

Research exploring the implant in the context of contraception was studied for healthy women primarily through integrated analyses of several Randomized Controlled Trials (RCTs) across multiple countries. This research base also includes larger, long-term observational cohort studies that studies monitored the use of the implant in real-world settings over several years.

These foundational studies monitored the primary outcome related to contraceptive effort using the Pearl Index, which is a calculation designed to show the number of pregnancies that occur per 100 women using the method for one year. The research examined outcomes for the period up to three years, which is the approved duration.


Evidence in Specific Populations

Initial Trial Populations

The initial clinical trials primarily included patients who were healthy adult women. These studies typically evaluated women whose body weights were within a specific range, often excluding those with very high body weight. This means that the results apply only to the populations studied and initial evidence for certain groups was limited.

Studies in Overweight and Obese Women

Later observational settings evaluating daily-life functioning and larger cohort studies were conducted to specifically examine the implant's contraceptive effort in women with higher Body Mass Index (BMI). Research has explored the concentration of the active hormone, etonogestrel, in the blood across these different weight categories. The data show patterns related to hormone levels that were observed in the studied populations throughout the study period, even in women with higher BMI.


Gaps and Uncertainty in the Research Landscape

Research highlights several areas where the evidence is limited and certainty remains low:

A significant limitation reported in the studies is the high rate of discontinuation by participants, which led to a lower number of people completing the full three years of the initial trials. This discontinuation was associated with factors such as changes in expected menstrual bleeding patterns, which was observed in some studies to be a frequent reason for early removal.

Furthermore, limited information for long-term outcomes is available, meaning the effects of the implant beyond the approved three-year duration are not fully established by pivotal trials. The data for certain groups remain insufficient, particularly for women at the highest levels of obesity over the full three years of use.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Nexplanon implant (FAQ)

Q: How quickly does the Nexplanon implant start protecting against pregnancy after insertion?

A: The onset of contraceptive protection depends on the timing of insertion relative to your menstrual cycle. If the implant is inserted within the first five days of a menstrual period, official information indicates it provides protection when inserted immediately.

If it is inserted at any other time, the use of a non-hormonal backup method, such as a condom, may be recommended or necessary for the first seven days.

Q: Is the Nexplanon implant the same as Implanon, or is there a difference?

A: Nexplanon is described in official documentation as an updated, second-generation version of the original Implanon device. A key difference is that Nexplanon contains barium sulfate, making it radiopaque (visible on X-ray). This feature was added to improve the ability of healthcare providers to locate the implant after insertion.

Q: Does the Nexplanon implant ever stop my period completely?

A: Yes, changes to the menstrual bleeding pattern are a very common occurrence. According to official product information, one of the changes that may be experienced is having no bleeding at all during the time of the period, which is clinically known as amenorrhea.

Q: How does the progestin hormone in Nexplanon differ from the hormones in combination birth control pills?

A: The Nexplanon implant is a progestin-only contraceptive, meaning it contains a single synthetic hormone: etonogestrel. Combination birth control pills, however, contain two types of hormones: a progestin and an estrogen hormone. This distinction defines the pharmacological class of the implant.

Q: Does the Nexplanon implant protect against sexually transmitted infections (STIs)?

A: No. Official medical sources clearly state that the Nexplanon implant, like all hormonal contraceptive methods, does not provide protection against HIV/AIDS or any other sexually transmitted infections (STIs).

Q: How soon can a person become pregnant after the Nexplanon implant is removed?

A: The return to fertility is generally prompt after the implant is removed by a healthcare professional. Official information suggests a person may become pregnant shortly after removal, as early as the first week the implant is taken out.

Q: Does the implant affect a person's future fertility after it is removed?

A: The Nexplanon implant is considered immediately reversible upon removal. Official medical data indicates there is no evidence that its prior use affects a person's ability to become pregnant in the future.

Q: Is the implant always visible or easily felt under the skin after insertion?

A: Immediately after the insertion procedure, the healthcare professional must check that the implant is in the arm by palpation (feeling for it). If the implant cannot be felt upon immediate check, additional tests may be required to confirm and locate its position.

Q: Is there any risk to the fetus if the implant is accidentally inserted during an existing pregnancy?

A: Use of the implant is contraindicated, meaning it must not be used, during a known or suspected pregnancy. Regulatory documentation indicates that based on experience with other hormonal contraceptives, the implant is not likely to cause birth defects.

Q: How does a person check or confirm that the Nexplanon implant is still correctly in place?

A: The presence of the implant is typically confirmed by feeling for it in the arm. If a person cannot feel the implant at any time, it is important to contact a healthcare professional immediately for confirmation. The implant’s radiopacity allows for confirmation via certain imaging tools.

Q: Is it necessary to use a backup birth control method immediately after the implant is inserted?

A: A backup, non-hormonal method is required only in certain circumstances. If insertion of the implant occurs after the fifth day of the menstrual cycle, a backup method is recommended for the first seven days where applicable.

Q: Can the implant interfere with medical imaging like X-rays or MRI scans?

A: The implant contains barium sulfate, a feature that makes it radiopaque, allowing it to be seen clearly on imaging such as X-ray or CT scans. Official labeling includes specific information regarding the safety of the device during MRI procedures.

Q: Are there any specific concerns for people who have a history of migraine headaches and want to use Nexplanon?

A: Headache is listed as a very common side effect in the regulatory documentation for the implant. Official information indicates that a history of headaches, including migraines, is a topic that should be discussed with a healthcare professional.

Q: What should a person do if they cannot feel the Nexplanon implant in their arm?

A: If a person is unable to feel the implant in their arm at any time, it is recommended to contact a healthcare professional immediately. The use of a non-hormonal backup method may be necessary until its presence is confirmed by a healthcare provider.

Q: Can the implant cause or be related to symptoms of a severe allergic reaction?

A: Yes, official labeling includes warnings that a person should seek immediate medical attention if they experience symptoms of a severe allergic reaction. These symptoms may include a swollen face, tongue, or throat, or trouble breathing or swallowing.

Q: What are the potential risks if the implant is inserted incorrectly or too deeply?

A: The procedure is designed to be performed only by trained healthcare professionals. Official warnings note that insertion that is too deep may cause difficulty with locating and removing the implant, potentially leading to the need for surgery.

Q: Is it common to have significant bruising or swelling at the insertion site?

A: Yes, the insertion procedure can result in local effects at the site. Documentation states that common complications at the insertion site may include pain, swelling, or bruising (hematoma) following the procedure.

Q: How is the implant removed, and is a local anesthetic always used?

A: The removal procedure must be performed by a healthcare professional. To remove the implant, the provider will first numb the area. Local anesthesia is typically used as part of the standard removal process before making a small incision to take the implant out.

Q: What should a patient know about the user card received after the implant is placed?

A: Official instructions indicate that patients receive a user card that serves as a vital record. This card records the exact insertion date, the final 3-year removal date, and the specific location (which arm) of the implant.

Q: Is the implant designed to prevent or reduce menstrual cramps?

A: The primary purpose and approval of the implant are for the prevention of pregnancy. However, the regulatory documentation lists dysmenorrhea (painful menstruation or cramps) as a Common side effect, indicating a potential effect on cramps.

Q: Does the implant affect the risk of ectopic pregnancy compared to using no contraception?

A: The overall risk of ectopic pregnancy (pregnancy outside the uterus) is very low for users because the implant is highly effective at preventing pregnancy. However, official warnings note that if a woman does become pregnant while using the implant, the likelihood of that pregnancy being ectopic is increased.

Q: Why is the Nexplanon implant typically inserted in the non-dominant upper arm?

A: Official administration instructions specify that the insertion site is the inner side of the non-dominant upper arm. This particular site is chosen as a procedural safeguard to help minimize the potential for injury to nerves or major blood vessels in the arm.

Q: What are the signs that a person should contact a healthcare provider urgently while using the implant?

A: It is advised to seek immediate medical attention for urgent symptoms described in the official warnings. These include signs of a severe allergic reaction, a sudden severe headache, or signs of a blood clot, such as unexplained pain or swelling in the lower leg or severe chest pain.

Q: Can the implant be inserted immediately after a miscarriage or abortion?

A: The timing for insertion varies depending on the circumstances. The implant can be inserted immediately after a first-trimester abortion or miscarriage. For a second-trimester abortion or miscarriage, official guidance recommends waiting until four weeks after the procedure.

Advertisements

How should Nexplanon implant be stored and disposed of?

The official storage and disposal guidelines for the NEXPLANON implant maintain product integrity and ensure proper handling of pharmaceutical waste.

Storage Requirements

Condition Regulatory Rule
Temperature Store at controlled room temperature (25 C / 77 F); excursions permitted between 15 C and 30 C (59 F and 86 F).
Handling Avoid storing at temperatures above 30 C (86 F).
Packaging Must remain in its original container until use and must be inserted by the expiration date.
Safety Keep the product out of the reach and sight of children.

Disposal Instructions

Both the removed implant and the single-use insertion applicator must be disposed of by the healthcare professional. Disposal must be in accordance with local regulations for the handling of biohazardous waste and must not be discarded in general household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nexplanon implant found in:

A-Z Index: